Clinical Trial Update: Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC [Phase 1, Phase 2]

View source ↗

Summary

Completed Phase 1/2 dose-escalation and efficacy study evaluating LAE001 with prednisone and afuresertib in metastatic castration-resistant prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Afuresertib (afuresertib)
• LAE001
• PREDNISONE (Prednisone)

Snippet

Sponsor: Laekna Limited | Conditions: Metastatic Castration-resistant Prostate Cancer | Phase 1, Phase 2 | Status: COMPLETED